GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anbio Biotechnology NNNN · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.08

+4.88%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$8.6m

FY2021FY2025

Net income

$6.4m

FY2021FY2025

Free cash flow

−$6.7m

FY2021FY2025

Shareholders' equity

$30.2m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue$8.6m$8.2m$6.7m$23.5m$4.4m
Research and development$201,305$454,227$134,700$200,000—
Operating income$5.8m$2.0m$2.0m$10.2m$2.5m
Net income$6.4m$2.4m$2.3m$10.0m$2.5m
Diluted earnings per share0.150.060.050.240.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets$30.2m$18.9m$15.8m$14.0m$4.9m
Cash and short-term investments$11.9m$11.8m$9.7m$8.7m$4.2m
Total liabilities$87,836$1.7m$993,060$1.4m$2.4m
Shareholders' equity$30.2m$17.2m$14.8m$12.5m$2.5m
Shares outstanding44m42m42m42m44m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−$6.7m$2.1m$898,367$4.4m$4.2m
Capital spending———−$3—
Free cash flow−$6.7m$2.1m$898,367$4.4m$4.2m

Latest quarters

By quarter end

Mar 2026Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue$4.7m$2.0m$5.0m−$3.1m$2.5m$1.2m$6.3m$2.9m
Operating income$2.8m$1.2m$3.7m−$1.9m−$1.7m−$801,499$3.9m$1.8m
Net income$3.0m$1.3m$4.1m−$2.1m−$1.3m−$611,901$3.9m$1.8m
Diluted earnings per share0.070.030.09-0.05-0.03-0.010.090.04
Cash from operations————$1.0m———
Total assets$30.2m$30.2m$32.5m$27.7m$18.9m$18.9m$18.9m$18.9m
Cash and short-term investments$11.9m$11.9m$15.8m$13.4m$11.8m$11.8m$10.3m$10.3m
Shareholders' equity$30.2m$30.2m$32.3m$27.5m$17.2m$17.2m$18.4m$18.4m

Financial ratios

Data as of 22 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Operating margin66.7%24.4%33.6%42.6%55.5%
Net margin74.1%29.0%33.6%42.5%57.3%
Return on equity21.2%13.8%15.2%79.8%100.0%
Return on assets21.2%12.5%14.3%71.7%51.6%
Free cash flow yield———2.8%—
Revenue growth5.6%21.9%-71.5%431.7%—
Earnings growth169.9%5.3%-77.5%294.8%—
Current ratio344.31x10.71x15.86x9.88x2.07x
Equity ratio99.7%90.9%93.7%89.9%51.6%
Interest coverage———1252.55x—
R&D as a share of sales2.3%5.5%2.0%0.8%—
Buybacks as a share of market value-3.8%0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-28.4%——
Operating income-17.3%——
Net income-13.8%——

Valuation history

At each fiscal year end

FY2025
Price to earnings206.1
Price to sales152.6

Market value over time

28 Feb 2025 to 21 Oct 2026, in USD

$282.9m$163.3m

Share price return

Finished calendar years

2025
Return424%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.